Supratek Pharma Inc. is a patient oriented oncology company dedicated to the discovery, rapid development and taking into to clinical practice innovative anticancer therapeutics desperately needed by cancer patients with tumors that resist available therapies. Many resistant cancers are at a metastatic stage. Late-stage metastatic cancers account for the majority of cancer deaths and represent one of the major unmet medical needs world-wide.
Since 1994, our scientists have steadily built on their cutting edge breakthrough discovery of Biotransport™ carrier and biological modification technology. Their deep understanding of cancer progression and metastasis formation has resulted in the successful translation of scientific discovery into pre-clinical development and novel clinical-stage anticancer drug candidates.
Thanks to its exciting science Supratek has attracted outstanding, highly creative and productive multidisciplinary individuals to its R&D, clinical development and management functions. Supratek has also established a consulting network of outstanding opinion leaders with recognized expertise in critical areas of cancer research and anticancer drug development. They assist the Company in designing winning drug development strategies.